Abstract
Abstract
Photodynamic therapy (PDT) is a cancer treatment that uses a photosensitizer and a specific wavelength of light. When tumor cells which have absorbed photosensitizer are exposed to the correct wavelength of light, reactive oxygen species are generated, resulting in tumor cell death. Poor tissue penetration of light is a major limitation in PDT, restricting its use to treatment of localized tumors. Light generation at the tumor area might increase the effectiveness of PDT and can expand its use for metastatic tumors. Infiltration of tumor-activated polymorphonuclear neutrophils (PMNs) produces luminescence in the presence of luminol; this bioluminescence has been used for tumor detection in pre-clinical trials. Based on this rationale, we hypothesized that luminol-based bioluminescence can cause targeted PDT in breast adenocarcinoma tumors in the presence of the photosensitizer 5-aminolevulinic acid (ALA). To test this hypothesis, BALB/c mice were transplanted with 4T1 mammary adenocarcinoma cells to establish a breast adenocarcinoma model. After tumor formation, ALA and luminol were administered to mice through intraperitoneal and intravenous routes, respectively. This treatment regimen was repeated six times and ALA alone/luminol alone/saline treated tumor-bearing mice were used as controls. Relative differences in the increase of tumor volume and final tumor weights were analyzed to test the treatment hypothesis. Analysis of the data showed that treatment with a combination of luminol and ALA as well as treatment with luminol alone results in breast adenocarcinoma tumor growth attenuation. This study gives evidence for the antitumor activity of luminol on breast adenocarcinoma, possibly through PDT.
Citation Format: Hamad S. Alshetaiwi, Tej B. Shrestha, Sivasai Balivada, Matthew T. Basel, Marla Pyle, Hongwang Wang, Stefan H. Bossmann, Deryl L. Troyer. Luminol-based in situ photodynamic therapy for breast adenocarcinoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4920. doi:10.1158/1538-7445.AM2014-4920